Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034700 | 0.95 | RAB9A (0.38) | RAB9ANPC1ALDH1A1PKMKMT2A | |
| SCHEMBL5032648 | 0.92 | ALDH1A1 (0.48) | RAB9ANPC1ALDH1A1PKMKMT2A | |
| SCHEMBL27643397 | 0.92 | POLB (0.44) | RAB9ANPC1ALDH1A1KMT2AGFER | |
| SCHEMBL14190194 | 0.91 | LRRK2 (0.38) | RAB9ANPC1PKMKMT2AGFER | |
| SCHEMBL5035159 | 0.91 | LRRK2 (0.38) | RAB9ANPC1PKMKMT2AGFER | |
| SCHEMBL5035165 | 0.91 | LRRK2 (0.38) | RAB9ANPC1PKMKMT2AGFER | |
| SCHEMBL5032544 | 0.91 | HTR2C (0.42) | RAB9ANPC1KMT2ALMNAGAA | |
| SCHEMBL5035125 | 0.91 | KMT2A (0.43) | RAB9ANPC1ALDH1A1KMT2AGAA | |
| SCHEMBL5035140 | 0.86 | HSD11B1 (0.41) | RAB9ANPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL5034572 | 0.86 | LMNA (0.40) | RAB9ANPC1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | claimed |
| JP-2007513193-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | claimed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | claimed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153962-A1 | Thiazole derivatives | CNR1, CNR2, GPR119 | RAB9A 1847/4885NPC1 313/4885ALDH1A1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.